Frontier Medicines on Thursday closed its oversubscribed $80 million Series C funding round, which it will use to advance its potentially first-in-class next-generation KRAS blocker FMC-376.
Tag Archive for: BMS
Saturday’s readout, which were presented at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium, could position BMS to challenge Merck’s dominant PD-1 blocker Keytruda.
BMS pushed back by a year the time frame for its current new-product portfolio to hit $10 billion in sales as the ramp-up of new drugs including anemia treatment Reblozyl, psoriasis drug Sotyktu, and multiple sclerosis drug Zeposia takes longer than expected.
The competitors posted promising survival data for their respective blockbuster PD-1 inhibitors—Keytruda and Opdivo—emphasizing the potential of these therapies in bladder cancer patients.
The abstracts, made available Tuesday ahead of the European Society for Medical Oncology Congress 2023, show strong efficacy data from some promising non-small cell lung cancer treatments.
Cellares, the first Integrated Development and Manufacturing Organization dedicated to clinical and industrial-scale cell therapy manufacturing, announced that global biopharmaceutical company and cell therapy leader Bristol Myers Squibb will enter a second proof-of-concept tech transfer process for the manufacture of a CAR-T cell therapy, as part of the Cellares Technology Adoption Partnership program. As part of this expanded agreement, Cellares will optimize, automate, and tech-transfer the additional CAR-T cell therapy process onto its automated manufacturing platform, the Cell Shuttle.
As the COVID-19 pandemic continues to recede, the top pharma companies intensified their focus into areas such as cancer and metabolic diseases to build up their pipelines, and their growth prospects, for the future.
Retiring BMS CEO Giovanni Caforio is handing off a company orders of magnitude different than it was at the beginning of his tenure.
Bristol Myers Squibb on Sunday announced that it has entered into a definitive merger agreement with cancer-focused biotech Mirati Therapeutics in a bid to grow its oncology franchise.
The deal is an expansion of an existing production agreement between the companies and just one of several deals with large pharma companies that the Korean biotech has scooped up this year.
